Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
250 participants
OBSERVATIONAL
2021-12-21
2026-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
NCT01570465
Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms
NCT04460950
Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response
NCT04104035
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital
NCT05558943
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.
All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients signed informed consent form
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turkish Hematology Association
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ilker Kurkcu
Role: STUDY_DIRECTOR
Sentez Cro
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Antalya Training and Research Hospital
Antalya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Volkan Karakus
Role: primary
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Karakus V, Pinar IE, Iltar U, Yenihayat EM, Polat MG, Celik S, Malkan UY, Cengiz Seval G, Dogan A, Akdeniz A, Ozbalci D, Ince I, Erdem R, Mehtap O, Kirkizlar HO, Kacmaz M, Deveci B, Aykas F, Korkmaz G, Yigit Kaya S, Afacan Ozturk HB, Sevindik OG, Can F, Cekdemir D, Aslan C, Bulbul H, Karabulut ZT, Maral S, Durusoy SS, Demirkan F, Goker H, Ozkalemkas F, Keklik M, Toprak SK, Karatas AF, Atas U, Alacacioglu I; Turkish Society of Hematology-Acute Leukemias Working Group. Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry. J Clin Med. 2025 Oct 18;14(20):7367. doi: 10.3390/jcm14207367.
Pinar IE, Celik S, Polat MG, Karatas AF, Dogan A, Iltar U, Cengiz Seval G, Malkan UY, Ince I, Yenihayat EM, Akdeniz A, Kacmaz M, Erdem R, Afacan Ozturk HB, Kirkizlar HO, Korkmaz G, Aykas F, Mehtap O, Deveci B, Sevindik OG, Can F, Ozbalci D, Bulbul H, Durusoy SS, Atas U, Keklik M, Toprak SK, Goker H, Demirkan F, Ozkalemkas F, Alacacioglu I, Karakus V; Turkish Society of Hematology-Acute Leukemias Working Group. Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project. BMC Cancer. 2025 Oct 10;25(1):1546. doi: 10.1186/s12885-025-14987-z.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AML_Registry
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.